Can-Fite BioPharma reported positive Phase 2a pancreatic cancer trial results with Namodenoson, showing safety and survival benefits, and plans a Phase 2b combo study. NeOnc Technologies is awaiting Phase 2a data for NEO100 with FDA designations and expanding globally, backed by insider and institutional buying. PMGC Holdings' NorthStrive Biosciences partnership achieved positive Phase III AI-driven drug discovery results targeting muscle preservation. These developments highlight biotech innovation in oncology, metabolic disease, and AI therapeutics, offering multiple upcoming catalysts for investors in the second half of 2026.
The global data center infrastructure market, valued at $297.07 billion in 2025, is projected to grow at a 10.9% CAGR to reach $752.12 billion by 2034. Growth is fueled by rising cloud adoption, AI workloads, digital transformation, and demand for en...
Dimensional Fund Advisors Ltd disclosed a sale of 730,460 ordinary shares of Beazley PLC, reducing its holding to 0.89% as of June 30, 2026. This transaction reflects a partial exit from their investment in Beazley PLC. The sale price per share was a...
The global pyrometer market, valued at $544.55 million in 2025, is projected to reach $1.15 billion by 2035, growing at a CAGR of 7.57%. This growth is fueled by rising industrial automation and expansion in semiconductor manufacturing, which increas...
Abeona Therapeutics announced it granted restricted stock awards to five new non-executive employees as an inducement to join the company, totaling up to 9,000 shares. These shares will vest over three years, contingent on continued employment. This ...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against BitGo Holdings, ADMA Biologics, and Erasca. The lawsuits allege these companies made false or misleading statements affe...
